Unchanged

Summary of findings {#CD003343-sec1-0001}
===================

###### Directly observed therapy (DOT) versus self‐administered TB treatment

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- -----------------------------
  **Directly observed therapy (DOT) versus self‐administered TB treatment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  **Patient or population:** Patients on TB treatment  **Settings:** Low‐, middle‐ or high‐income countries  **Intervention:** DOT  **Comparison:** Self‐administered therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                      

  **Self‐administered therapy**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **DOT**                                                                                                                                                     

  **Cure**   Follow‐up: up to 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **617 per 1000**                                **666 per 1000**   (561 to 784)   **RR 1.08**   (0.91 to 1.27)       1645  (5 trials)                       ⊕⊕⊕⊝  **moderate**^1,2,3,4^

  **Treatment completion**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **709 per 1000**                                **751 per 1000**   (680 to 829)   **RR 1.07**   (0.96 to 1.19)       1839  (6 trials)                       ⊕⊕⊕⊝  **moderate**^1,2,3,4^
  Follow‐up: 2 to 8 months^5^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  The basis for the **assumed risk** is the median control group risk across studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** confidence interval; **RR:** risk ratio; **DOT:** directly observed therapy; **TB:** tuberculosis.                                                                                                                                                                                                                                                                                                                                    

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- -----------------------------

^1^No serious risk of bias: three trials adequately described allocation concealment. Exclusion of trials at unclear or high risk of bias did not substantially change the result.  ^2^Downgraded by 1 for inconsistency: trials include qualitative differences in effect size and direction. The benefit reached standard levels of statistical significance in the two trials where those receiving self‐administered therapy had less frequent contact with health services compared to the directly observed group, so any effect probably due to confounding.  ^3^No serious indirectness: The trials were conducted in low‐, middle‐ and high‐income countries between 1995 and 2008.  ^4^No serious imprecision: The analysis is adequately powered to detect clinically important differences between treatment arms.  ^5^Some trials checked for completion of intensive phase treatment and others the completion of the whole therapy, hence the 2 to 8 months.

###### Home DOT versus clinic DOT

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- ---------------------------
  **Home DOT versus clinic DOT**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  **Patient or population:** Patients with TB treatment  **Settings:** Low‐, middle‐ or high‐income countries  **Intervention:** Home observation  **Comparison:** Clinic observation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   
  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                      
  **Clinic observation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **Home observation**                                                                                                                                        
  **Cure**   Follow‐up: up to 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **492 per 1000**                                **502 per 1000**   (433 to 580)   **RR 1.02**   (0.88 to 1.18)       1556  (4 trials)                       ⊕⊕⊕⊝  **moderate**^1,2,3^
  **Treatment completion**^4^   Follow‐up: 2 to 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **751 per 1000**                                **781 per 1000**   (684 to 879)   **RR 1.04**   (0.91 to 1.17)       1029  (3 trials)                       ⊕⊕⊕⊝  **moderate**^1,2,3^
  The basis for the **assumed risk** is the median control group risk across studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** confidence interval; **RR:** risk ratio; **DOT:** directly observed therapy; **TB:** tuberculosis.                                                                                                                                                                                                                                                                                                                                    
  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- ---------------------------

^1^Downgraded by 1 for risk of bias: selection bias is probable in one trial, [Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}, as there was no blinding and no allocation concealment. In [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}, sequence generation and allocation concealment were unclear and there was no blinding. This could bias the measurement of treatment completion.  ^2^No serious indirectness: The trials were conducted in low‐, middle‐ and high‐income countries between 1995 and 2008.  ^3^No serious imprecision: The analysis is adequately powered to detect clinically important differences between treatment arms.  ^4^Some trials checked for completion of intensive phase treatment and others the completion of the whole therapy, hence the 2 to 6 months.

###### Summary of findings table 3

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ---------------------------------- ---------------------------------- -------------------------------------- -----------------------
  **Community DOT versus family DOT**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **Patient or population:** Patients on TB treatment  **Settings:** Low‐, middle‐ or high‐income countries  **Intervention:** Community DOT  **Comparison:** Family DOT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**      **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                       

  **Family DOT**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **Community DOT**                                                                                                                                            

  **Cure**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **766 per 1000**                                **781 per 1000**   (659 to 927)    **RR 1.02** (0.86 to 1.21)         1493\                                  ⊕⊕⊕⊝  **moderate**^1^
  Follow‐up: up to 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       (2 trials)                             

  **Treatment completion**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **827 per 1000**                                **869 per 1000**   (744 to 1000)   **RR 1.05** (0.90 to 1.22)         1493\                                  ⊕⊕⊝⊝  **low**^1,2^
  Follow‐up: 2 to 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (2 trials)                             

  \*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** confidence interval; **RR:** risk ratio; **DOT:** directly observed therapy; **TB:** tuberculosis.                                                                                                                                                                                                                                                                                       

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ---------------------------------- ---------------------------------- -------------------------------------- -----------------------

^1^Downgraded by 1 for risk of bias. Both trials had unclear random sequence generation and recruitment bias could not be ruled out for [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}.  ^2^Downgraded by 1 for risk of bias for the outcome of treatment completion as there was no allocation concealment and selective reporting could not be ruled out in [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"}.

###### DOT versus self‐administered therapy for intravenous drug users

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------- ----------------------
  **DOT versus self‐administered therapy for intravenous drug users**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Patient or population:** Patients on TB treatment  **Settings:** Low‐, middle‐ or high‐income countries  **Intervention:** DOT  **Comparison:** Self‐administered treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**   **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                    

  **Self‐administered therapy**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **DOT**                                                                                                                                                   

  **Treatment completion**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **79 per 100**                                  **79 per 1000**   (70 to 89)    **RR 1.00** (0.88 to 1.13)         300  (1 trial)                         ⊕⊕⊝⊝  **low**^1,2,3^
  Follow‐up for 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  \*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** confidence interval; **RR:** risk ratio; **DOT:** directly observed therapy; **TB:** tuberculosis.                                                                                                                                                                                                                                                                                    

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------- ----------------------

^1^Downgraded by 1 for risk of bias. There was no blinding of outcome assessment and allocation concealment was unclear and treatment completion can be a bit subjective hence the results might be biased. The level of completeness to follow‐up was 88%.  ^2^Downgraded by 1 for indirectness. The self‐administered group had a 10 dollar stipend which is may have enhanced adherence in this group.  ^3^There may have been some imprecision. The study was had a small sample size and may have been underpowered to detect clinically important differences.

Background {#CD003343-sec1-0002}
==========

Description of the condition {#CD003343-sec2-0001}
----------------------------

Tuberculosis (TB) remains a leading cause of death in low‐ and middle‐income countries despite the availability of effective treatments. In 2012, the World Health Organization (WHO) estimated that there were 8.6 million people infected with TB, of whom 1.3 million died ([WHO 2013](#CD003343-bbs2-0060){ref-type="ref-list"}). Most people infected with *Mycobacterium tuberculosis* develop \'latent TB\', where the bacteria are contained by the person\'s immune system and they do not develop symptoms. The risk of progression to active TB and development of symptoms is about 10% over the course of a lifetime ([Frieden 2003](#CD003343-bbs2-0035){ref-type="ref-list"}), but co‐infection with human immune deficiency virus (HIV) increases this risk to about 10% per year ([Sepkowitz 1995](#CD003343-bbs2-0052){ref-type="ref-list"}).

The WHO currently recommends at least six months of treatment for active disease, and 12 months for latent TB ([Smieja 2010](#CD003343-bbs2-0053){ref-type="ref-list"}; [WHO 2010](#CD003343-bbs2-0059){ref-type="ref-list"}). These long durations of treatment can be difficult for patients to adhere to, especially once they are well and need to return to work. Poor adherence can lead to relapse and even death in individuals, and also has important public health consequences, such as increased transmission and the development of drug resistance ([Hirpa 2013](#CD003343-bbs2-0039){ref-type="ref-list"}; [Moonan 2011](#CD003343-bbs2-0048){ref-type="ref-list"}).

[Munro 2007](#CD003343-bbs2-0049){ref-type="ref-list"} synthesized evidence from qualitative studies among patients and health workers and identified eight factors that influence adherence:

Organization of treatment and care for TB patients.Interpretation of illness and wellness by the patient.Financial cost.Patient knowledge, attitudes and beliefs about treatment.Law and immigration status.Gender and substance abuse.Drug side effects.Influence of the family, community and peers.

We adapted an existing conceptual framework by [van den Boogaard 2012](#CD003343-bbs2-0056){ref-type="ref-list"} to develop a model for understanding approaches to improving adherence ([Figure 1](#CD003343-fig-0001){ref-type="fig"}).There are health system level barriers (staff, inconvenient location, expensive and a poorly organized healthcare system) and personal level barriers (stigmatisation, poverty, competing demands and health beliefs) to adherence and the patient has to work through these barriers in order to be adherent. Healthcare workers have devised several strategies targeted at some of the key barriers to improve adherence, some of which are addressed by Cochrane Reviews:

![Factors influencing adherence and possible intervention points.](nCD003343-AFig-FIG01){#CD003343-fig-0001}

Reminder systems and late patient tracers in the diagnosis and management of TB ([Liu 2008](#CD003343-bbs2-0043){ref-type="ref-list"}).Patient education and counselling for promoting adherence to treatment for TB ([M\'Imunya 2012](#CD003343-bbs2-0045){ref-type="ref-list"}).Material incentives and enablers in the management of TB ([Lutge 2012](#CD003343-bbs2-0044){ref-type="ref-list"}).Contracts: written or verbal agreements to return for an appointment or course of treatment ([Bosch‐Capblanch 2007](#CD003343-bbs2-0029){ref-type="ref-list"}).

Description of the intervention {#CD003343-sec2-0002}
-------------------------------

\'Directly observed therapy\' (DOT) is one component of a wider WHO strategy called \'Directly Observed Therapy Short course\' (DOTS). This strategy incorporates wide ranging health system improvements, political commitment to improving TB programmes, improved TB laboratory services, free TB drugs for all TB patients, and accurate documentation and monitoring of TB diagnosis and treatment outcomes ([WHO 2002](#CD003343-bbs2-0058){ref-type="ref-list"}). The DOT component is an attempt to improve adherence by active monitoring and recording of the consumption of each and every drug dose by an \'observer\' acceptable to the patient and the health system ([Hopewell 2006](#CD003343-bbs2-0040){ref-type="ref-list"}). This approach was first adopted in studies in Madras, India and Hong Kong as early as the 1960s ([Bayer 1995](#CD003343-bbs2-0028){ref-type="ref-list"}), and is now considered a core component of TB programmes by the WHO to ensure cure and prevent the emergence of drug resistance ([Chien 2013](#CD003343-bbs2-0032){ref-type="ref-list"}; [Hirpa 2013](#CD003343-bbs2-0039){ref-type="ref-list"}). Proponents of DOT argue that the close monitoring has a social effect and acts as a peer pressure which leads to behavior change towards improved adherence ([Macq 2003](#CD003343-bbs2-0046){ref-type="ref-list"}) and it has strong proponents ([Chaulk 1998](#CD003343-bbs2-0031){ref-type="ref-list"}; [Frieden 2007](#CD003343-bbs2-0036){ref-type="ref-list"}). However, to opponents it has been seen as a coercive model which leaves the patient as a passive recipient of therapy thereby eroding the gains made in involving patients in management of their own health ([Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}).

The initial Cochrane Review ([Volmink 1997](#CD003343-bbs2-0061){ref-type="ref-list"}) and subsequent updates ([Volmink 2000a](#CD003343-bbs2-0062){ref-type="ref-list"}; [Volmink 2001](#CD003343-bbs2-0063){ref-type="ref-list"}; [Volmink 2003](#CD003343-bbs2-0064){ref-type="ref-list"}; [Volmink 2006](#CD003343-bbs2-0065){ref-type="ref-list"}; [Volmink 2007](#CD003343-bbs2-0066){ref-type="ref-list"}) challenged the dogma that DOT improved cure and thus helped prevent drug resistance developing. The debate has continued, with some even advocating for a shift of resources away from DOT programmes ([Barbara 2013](#CD003343-bbs2-0027){ref-type="ref-list"}; [Gross 2009](#CD003343-bbs2-0037){ref-type="ref-list"}; [Moonan 2011](#CD003343-bbs2-0048){ref-type="ref-list"}; [Pasipanodya 2013](#CD003343-bbs2-0050){ref-type="ref-list"}). There are also debates as to the best delivery of DOT, for example, should it be through healthcare workers or family members ([Anuwatnonthakate 2008](#CD003343-bbs2-0026){ref-type="ref-list"}; [Dick 2005](#CD003343-bbs2-0033){ref-type="ref-list"}).

Why it is important to do this review {#CD003343-sec2-0003}
-------------------------------------

Full implementation of DOT requires considerable resources. For example, in Pakistan it has been shown that direct observation at a health facility costs two times more than self‐supervision (USD310 versus USD164). Therefore, it is important to evaluate the effects in order to inform decisions about whether the benefits are worth investing in ([Khan 2003](#CD003343-bbs2-0042){ref-type="ref-list"}). This Cochrane Review is an update of [Volmink 2007](#CD003343-bbs2-0066){ref-type="ref-list"}.

Objectives {#CD003343-sec1-0003}
==========

To evaluate DOT compared to self‐administered therapy in people on treatment for active TB or on prophylaxis to prevent active disease. We also compare the effects of different forms of DOT.

Methods {#CD003343-sec1-0004}
=======

Criteria for considering studies for this review {#CD003343-sec2-0004}
------------------------------------------------

### Types of studies {#CD003343-sec3-0001}

Individually randomized controlled trials (RCTs) or cluster‐RCTs. We also included quasi‐RCTs.

### Types of participants {#CD003343-sec3-0002}

People on treatment for active TB or receiving prophylaxis to prevent the development of active TB disease.

### Types of interventions {#CD003343-sec3-0003}

#### Intervention {#CD003343-sec4-0001}

DOT where a health worker, community volunteer or family member, routinely observes participants taking their antituberculous drugs.

#### Control {#CD003343-sec4-0002}

Self‐administered therapy or an alternative form of DOT.

### Types of outcome measures {#CD003343-sec3-0004}

#### Primary {#CD003343-sec4-0003}

Cure (having a negative sputum smear test in the last month of treatment having been smear‐positive initially).Treatment completion.Development of clinical TB (in trials of drug prophylaxis).

#### Secondary {#CD003343-sec4-0004}

Proportion of outpatient appointments attended.

Search methods for identification of studies {#CD003343-sec2-0005}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press and in progress).

### Databases {#CD003343-sec3-0005}

We searched the following databases using the search terms and strategy described in [Appendix 1](#CD003343-sec2-0013){ref-type="app"}: Cochrane Infectious Diseases Group (CIDG) Specialized Register (13 January 2015); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (1966 to 13 January 2015); EMBASE (1974 to 13 January 2015); and LILACS (1982 to 13 January 2015). We also searched the *meta*Register of Controlled Trials (*m*RCT) using \'tuberculosis AND DOT\*\' (13 January 2015).

### Researchers and organizations {#CD003343-sec3-0006}

For unpublished and ongoing trials, we contacted individual researchers working in the field and the following organizations: WHO, the International Union Against Tuberculosis and Lung Disease, and the Centers for Disease Control and Prevention (CDC).

### Reference lists {#CD003343-sec3-0007}

We also checked the reference lists of all studies identified by the above methods.

Data collection and analysis {#CD003343-sec2-0006}
----------------------------

### Selection of studies {#CD003343-sec3-0008}

We independently applied the inclusion criteria to all identified trials. We used the titles and abstracts of the identified citations to exclude trials that clearly did not meet the inclusion criteria. If either review author judged that the trial might be eligible for inclusion, we obtained the full text article. We independently screened the full text articles of selected trials to confirm eligibility and resolved any disagreements by discussion.

### Data extraction and management {#CD003343-sec3-0009}

We independently extracted the data and checked whether trial authors had conducted an intention‐to‐treat analysis. We contacted trial authors to obtain missing information and to clarify issues. We resolved discrepancies through discussion. For the outcomes, we extracted the number of participants experiencing the event.

### Assessment of risk of bias in included studies {#CD003343-sec3-0010}

We independently evaluated the methodological quality of each trial, classifying the generation of allocation sequence and concealment of allocation as either adequate, inadequate or unclear, according to [Jüni 2001](#CD003343-bbs2-0041){ref-type="ref-list"}. We classified blinding as adequate if the trial authors took steps to ensure the people recording the main outcome of the trial were blinded to the assigned interventions, and inadequate if this was not the case or if there was no mention of attempts to blind the observers. We assessed completeness of follow‐up as adequate if 90% or more of the enrolled participants had outcome data reported, inadequate if less than 90% of the participants had outcome data reported, or unclear if not mentioned in the trial.

### Measures of treatment effect {#CD003343-sec3-0011}

For dichotomous outcomes, we calculated the results using the risk ratio (RR). We presented the effect estimates with 95% confidence intervals (CIs).

### Assessment of heterogeneity {#CD003343-sec3-0012}

We looked for statistical heterogeneity by inspecting the forest plots for overlapping CIs, applying the Chi^2^ test (P value \< 0.10 considered statistically significant) and the I^2^ statistic (I^2^ value of 50% used to denote moderate levels of heterogeneity). We assessed whether a difference in the intensity of supervision between the intervention and control group could explain heterogeneity.

### Data synthesis {#CD003343-sec3-0013}

We used [Review Manager 5](#CD003343-bbs2-0051){ref-type="ref-list"} to analyse the data, using risk ratio (RR) with 95% CIs to assess estimates of effect. We used the fixed‐effect model when there was no statistically significant heterogeneity (Chi^2^ test, P \> 0.1) and a random‐effects model when heterogeneity was present (I^2^ statistic \> 50). We assessed the quality of the evidence using the GRADE approach.

Results {#CD003343-sec1-0005}
=======

Description of studies {#CD003343-sec2-0007}
----------------------

Eleven trials, enrolling 5662 participants, met the inclusion criteria (*see* \'[Characteristics of included studies](#CD003343-sec2-0016){ref-type="sec"}\'), and we excluded 13 studies for the reasons listed in the \'[Characteristics of excluded studies](#CD003343-sec2-0017){ref-type="sec"}\' table.

Nine included trials were individually RCTs, and two were cluster‐RCTs ([Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}; [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}). One trial used a quasi‐random method of allocation ([MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}).

Three trials were conducted in low‐income countries (Tanzania: [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}; [Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}; Nepal: [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}); six in middle‐income countries (Taiwan: [Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}; Pakistan: [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}; Thailand: [Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}; South Africa: [Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}; [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}; and Swaziland: [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"}); and two were from high‐income countries (Australia: [MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}; USA: [Chaisson 2001 USA](#CD003343-bbs2-0001){ref-type="ref-list"}).

### Populations targeted {#CD003343-sec3-0014}

Ten trials evaluated DOT in people on treatment for active TB, and one evaluated directly observed prophylaxis in intravenous drug users (see [Table 9](#CD003343-tbl-0009){ref-type="table"}; [Table 10](#CD003343-tbl-0010){ref-type="table"}; [Table 11](#CD003343-tbl-0011){ref-type="table"}).

###### Summary of interventions in trials of DOT versus self‐administered

  ---------------------------------------------------------------------------- ------------------------- ------------------------------- ---------------------------------------- ------------------- ---------------------------------------------- ---------------------------------------- --------------------------- --------- --------------
  **Trial ID**                                                                 **DOT**                   **Self administered therapy**                                                                                                                                                                                              

  **Who observed?**                                                            **Where?**                **How often?**                  **Adherence recorded at each contact**   **Cure**            **Frequency of contact with health service**   **Adherence recorded at each contact**   **Cure**                              

  **Intensive phase**                                                          **Consolidation phase**                                                                                                                                                                                                                              

  [**Zwarenstein 1998 ZAF**](#CD003343-bbs2-0010){ref-type="ref-list"}         Nurses                    Clinic                          5 times per week                         3 times per week    Yes                                            38%\                                     Weekly                      Yes       51%\
                                                                                                                                                                                                                                                     (42/111)                                                                       (31/61

  [**Zwarenstein 2000 ZAF**](#CD003343-bbs2-0011){ref-type="ref-list"}         Nurse                     Clinic                          5 times per week                         3 times per week    Yes                                            57%\                                     Weekly                      Yes       41%\
                                                                                                                                                                                                                                                     (31/54)                                                                        (9/22)

  Lay health worker                                                            Lay health workers home                                                                                                                                                                                                                              

  [Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}**^1^**   Healthcare worker         Clinic                          Daily                                    Daily               Yes                                            76%  (315/414)                           Monthly                     Unclear   67%\
                                                                                                                                                                                                                                                                                                                                    (283/422)

  Community health worker                                                      Home                      Daily                           Daily                                                                                                                                                                                      

  Family member                                                                Home                      Daily                           Daily                                                                                                                                                                                      

  [**Walley 2001 PAK**](#CD003343-bbs2-0007){ref-type="ref-list"}              Healthcare worker         Clinic                          6 times per week                         2 times per month   Yes                                            59%\                                     Every two weeks             Unclear   62%\
                                                                                                                                                                                                                                                     (199/335)                                                                      (100/162)

  Community health worker                                                      Home                                                                                                                                                                                                                                                 

  Family member                                                                Home                      Daily                           Daily                                                                                                                                                                                      

  [MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}**^2^**        Family member             Home                            Daily                                    Daily               Yes                                            Not reported                             Monthly                     Yes       Not reported

  [Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}**^3^**            Case manager or\          Hospital                        Daily                                    Once per week       Yes                                            94%\                                     Monthly unscheduled visit   Yes       69%\
                                                                               Hospital care                                                                                                                                                         (30/32)                                                                        (22/32)
  ---------------------------------------------------------------------------- ------------------------- ------------------------------- ---------------------------------------- ------------------- ---------------------------------------------- ---------------------------------------- --------------------------- --------- --------------

^1^In [Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"} patients could choose which observer they preferred and there a more intense supervision of observers in the intensive phase.  ^2^In [MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"} nurses made weekly calls to the patients who were observed by a family member.  ^3^In [Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"} the case manager directly supervised medicine intake for first two months (Intensive phase), then self‐administration with weekly unscheduled visit.

###### Interventions comparing home versus clinic direct observation

  ---------------------------------------------------------------------- ------------------------------------ ----------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------- ---------------- --------------- ------------------ ----------------- -----------
  **Trial ID**                                                           **DOT at patient\'s home**           **DOT at clinic**                                                                                                                                                                                                                         

  **Who observed?**                                                      **How often?**                       **Supervision of observer**   **Cure**                  **Who observed?**                                                                                           **How often?**   **Cure**                                             

  **Intensive phase**                                                    **Consolidation phase**              **Intensive phase**           **Consolidation phase**                                                                                                                                                                                     

  [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}**^1^**     Family member                        Daily                         Not described             Observers collected drugs from the clinic every 2 weeks                                                     55%\             Health worker   6 times per week   Self‐supervised   64%\
                                                                                                                                                                                                                                                                                  (91/165)                                                              (108/170)

  [Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}**^1^**   Family member or former TB patient   Daily                         Self‐supervised           Observers collected drugs from clinic weekly and spot checks were conducted by health worker                43%\             Health worker   Daily              Self‐supervised   43%\
                                                                                                                                                                                                                                                                                  (111/260)                                                             (141/327)

  [**Zwarenstein 2000 ZAF**](#CD003343-bbs2-0011){ref-type="ref-list"}   Lay health worker^2^                 \'Several times a week\'      Not described             Observer collected drugs monthly                                                                            57%\             Health worker   5 times a week     3 times a week    41%\
                                                                                                                                                                                                                                                                                  (31/54)                                                               (24/58)

  [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}**^1^**     Community volunteer                  Daily                         Self‐supervised           Observer was visited every two weeks by the health worker and every month by the district co‐ordinator^3^   53%\             Health worker   Daily              Self‐supervised   49%\
                                                                                                                                                                                                                                                                                  (117/221)                                                             (148/301)
  ---------------------------------------------------------------------- ------------------------------------ ----------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------- ---------------- --------------- ------------------ ----------------- -----------

^1^In [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}, [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"} and [Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"} observation was during the intensive phase, while in the clinic observation arm of [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"} it continued in the consolidated phase.  ^2^In [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"} the observation took place in the lay health worker\'s home, not the patient\'s home.  ^3^In [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"} there was additional supervision by the district coordinator.

###### Interventions comparing family‐administered DOT versus community health worker DOT

  ----------------------------------------------------------------- ------------------------- --------------------- ------------------------- ----------------------------- ----------------------------------------------------------- ------------------------- --------------------------------- ------- -------
  **Trial ID**                                                      **Who observed?**         **Where?**            **How often?**            **Additional intervention**   **Who observed?**                                           **Where?**                **How often?**                            

  **Intensive phase**                                               **Consolidation phase**   **Intensive phase**   **Consolidation phase**                                                                                                                                                                 

  [**Newell 2006 NPL**](#CD003343-bbs2-0006){ref-type="ref-list"}   Family member             Patient\'s home       Daily                     Daily                         Drugs supplied to supervisor every week                     Community health worker   Patient\'s home^1^                Daily   Daily

  [**Wright 2004 SWZ**](#CD003343-bbs2-0009){ref-type="ref-list"}   Family member             Patient\'s home       Daily                     Daily                         Patient reviewed at the diagnostic centre once per month\   Community health worker   Community health worker\'s home   Daily   Daily
                                                                                                                                                                            Recorded in a patient adherence card                                                                                            
  ----------------------------------------------------------------- ------------------------- --------------------- ------------------------- ----------------------------- ----------------------------------------------------------- ------------------------- --------------------------------- ------- -------

^1^In [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"} the community health worker mainly visited the patients at their homes but occasionally the patients came to the health worker\'s home.

Six trials compared DOT with self‐administered therapy:

[Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"} included two arms in two locations (Elsies River and Khayelitsha); [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"} was the same trial containing data from one of these two locations, and had an additional arms (lay health worker administered DOT). The control arms (self‐administered treatment) were therefore the same for Elsies River in both trials, and so in the meta‐analysis we adjusted the data to ensure they were not counted twice.[Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"} allowed participants to choose between DOT by a health worker, community leader or family member; 85% chose the latter.[Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"} compared DOT by a health worker or community health worker with DOT by a family member and with self‐administration of treatment.[MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"} evaluated DOT by a family member compared to self‐administration.[Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"} had DOT by case managers; there were three arms; weekly observation, monthly observation and the control group was patients admitted to hospital (Inpatient care).

Four trials compared different forms of DOT:

[Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"} compared community health worker observation to family member observation.[Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"} trials compared DOT by a family member with either DOT by a health worker at a health facility or DOT by a community health worker.[Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"} compared community health worker observation to family member observation coupled with a once per week visit by a community health worker.[Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"} compared a community health worker DOT at home to DOT at a health facility.

One trial evaluated DOT in injecting (intravenous) drug users in the USA:

[Chaisson 2001 USA](#CD003343-bbs2-0001){ref-type="ref-list"} involved intravenous drug users, and studied DOT by an outreach nurse with self‐administration either with monthly peer support or monthly clinic visits.

### Intensity of supervision {#CD003343-sec3-0015}

Intensity of supervision varied in the included trials. For the six RCTs of DOT compared to self‐administered treatment, three trials appeared to be a direct comparison of healthcare worker administered DOT versus self‐administered. Another three trials appeared to have more intense supervision in the DOT arm only, with health workers visiting patients at home every two weeks. In [Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}, community health workers and family members received additional supervision by health centre staff once every two weeks. In [MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}, nurses had weekly calls to the patients who were observed by family members. In [Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"} the case manager visited the patients in the intervention arm and was supervised by weekly unscheduled supervision. In the control group of these trials no such intensive supervision was described.

### Adjustment for clustering {#CD003343-sec3-0016}

Both cluster‐RCTs adjusted for clustering appropriately: standard error of the coefficients for clustering on units corrected using the Huber‐White‐Sandwich method ([Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}); and, in [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}, using the coefficient of variation between clusters.

Risk of bias in included studies {#CD003343-sec2-0008}
--------------------------------

We have summarized the \'Risk of bias\' assessments [Figure 2](#CD003343-fig-0002){ref-type="fig"} and [Figure 3](#CD003343-fig-0003){ref-type="fig"}, and have listed the reasons in the [Characteristics of included studies](#CD003343-sec2-0016){ref-type="sec"} section.

![Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial.](nCD003343-AFig-FIG02){#CD003343-fig-0002}

![Risk of bias graph: review authors\' judgements about each risk of bias item presented as percentages across all included trials.](nCD003343-AFig-FIG03){#CD003343-fig-0003}

### Allocation {#CD003343-sec3-0017}

Seven trials used adequate methods to generate a random sequence: computer‐generated random sequences ([Chaisson 2001 USA](#CD003343-bbs2-0001){ref-type="ref-list"}; [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}; [Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}; [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}), a random‐number table ([Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}), coin tossing ([Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}) or drawing of lots from a basket ([Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}). One trial used alternate allocation, which was an inadequate randomization method ([MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}). The remaining trials reports did not provide information ([Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}; [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}; [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"}).

Four trials employed adequate methods for concealing allocation ([Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}; [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}; [Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}; [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}). Five trials had unclear allocation concealment ([Chaisson 2001 USA](#CD003343-bbs2-0001){ref-type="ref-list"}; [Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}; [Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}; [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}; [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"}) and the remaining two trials did not use allocation concealment ([MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}; [Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}).

### Blinding {#CD003343-sec3-0018}

Only four trials blinded outcome assessment ([MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}; [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}; [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}; [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"}). It was not used in three trials ([Chaisson 2001 USA](#CD003343-bbs2-0001){ref-type="ref-list"}; [Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}; [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}) and unclear in the remaining trials ([Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}; [Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}; [Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}; [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}).

### Incomplete outcome data {#CD003343-sec3-0019}

Two trials excluded more than 10% of participants from the analyses ([Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}; [Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}). A further three trials did not provide sufficient information to assess this aspect of trial quality ([MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}; [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}; [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}). The remaining trials had adequate follow‐up.

### Selective reporting {#CD003343-sec3-0020}

We found no evidence of selective reporting.

### Other potential sources of bias {#CD003343-sec3-0021}

[Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"} had a control group which was inpatient based. We have not included this group in our analyses. Two trials had the same control groups ([Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}; [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}; see [Table 9](#CD003343-tbl-0009){ref-type="table"}).

[Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"} had one cluster in the community observed arm lost to follow‐up and we therefore did not include it in the final analysis. Two cluster‐RCTs had cluster adjustment.

Effects of interventions {#CD003343-sec2-0009}
------------------------

See: [Table 1](#CD003343-tbl-0001){ref-type="table"}; [Table 2](#CD003343-tbl-0002){ref-type="table"}; [Table 3](#CD003343-tbl-0003){ref-type="table"}; [Table 4](#CD003343-tbl-0004){ref-type="table"}

### 1. DOT versus self‐administered therapy {#CD003343-sec3-0022}

The details of the interventions are described in [Table 9](#CD003343-tbl-0009){ref-type="table"}; and see [Table 1](#CD003343-tbl-0001){ref-type="table"}.

Six trials compared DOT and self‐administered therapy. The observers were described as either nurses ([Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}; [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}), healthcare workers ([Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}; [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}), community health workers ([Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}; [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}), lay health workers ([Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}), case managers ([Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}) or family members ([Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}; [MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}; [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}). In one trial participants were allowed to choose either a healthcare worker, a community health worker or a family member ([Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}).

Overall TB cure was low with self‐administered therapy, ranging from 41% to 69% across trials, but on average this did not substantially improve with DOT (RR 1.08, 95% CI 0.91 to 1.27; five trials, 1645 participants, *moderate quality evidence*; [Analysis 1.1](#CD003343-fig-00101){ref-type="fig"}). However, there was moderate statistical heterogeneity between trials (I^2^ statistic = 68%; P = 0.01), with two trials finding benefits which reached standard levels of statistical significance ([Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}; [Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}). These differential effects may be explained by differences in the intensity of follow‐up between the intervention and control arms ([Analysis 1.2](#CD003343-fig-00102){ref-type="fig"}). However it is important to note that these two trials were also at unclear or high risk of selection bias and detection bias.

[Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"} is the largest trial of DOT to date and found a higher TB cure with the intervention (76% versus 67%; RR 1.13, 95% CI 1.04 to 1.24; one trial, 836 participants). This trial had the least supervised control group (patients picked up their medication monthly), and one of the most intensely supervised intervention groups (doses were directly observed daily by a choice of health worker, community health worker or family member, and a health worker visited the patient at home every two weeks to check on adherence). This difference in intensity was similar in the second trial showing a difference (94% versus 69%; RR 1.36, 95% CI 1.06 to 1.75; one trial, 64 participants), but this trial was small and underpowered to have full confidence in this effect ([Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}).

Similarly, TB treatment completion ranged from 59% to 78% in those allocated to self‐administration, and on average did not substantially improve with DOT (RR 1.07, 95% CI 0.96 to 1.19; six trials, 1839 participants, *moderate quality evidence*; [Analysis 1.3](#CD003343-fig-00103){ref-type="fig"}). There was again moderate heterogeneity between trials (I^2^ = 57%; P = 0.04), with the same two trials finding statistically significant benefits ([Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}; [Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}).

Different levels of monitoring in the self‐administered groups did not yield substantially different levels of completion. (Self‐treatment group: monthly monitoring RR 1.12, 95% 0.95 to 1.31; three trials, 1073 participants; every two weeks: RR 0.99, 95% 0.87 to 1.14; one trial, 497 participants); weekly monitoring RR 1.04, 95% 0.74 to 1.46; two trials, 269 participants; [Analysis 1.4](#CD003343-fig-00104){ref-type="fig"}).

### 2. Home observation versus clinic observation {#CD003343-sec3-0023}

The trials are described in [Table 10](#CD003343-tbl-0010){ref-type="table"}; and see [Table 2](#CD003343-tbl-0002){ref-type="table"}.

Four trials compared home with clinic observation. Two tested family member direct observation against direct observation at clinic ([Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}; [Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}) while the other two tested community health worker home visits to direct observation at clinic ([Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}; [Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}).

TB cure was generally low for both the home observation groups (ranging from 43% to 57%) and for clinic observation (ranging from 41% to 64%). On average there was little or no difference between the two strategies (RR 1.02, 95% CI 0.88 to 1.18; four trials, 1556 participants, *moderate quality evidence*; [Analysis 2.1](#CD003343-fig-00201){ref-type="fig"}).

Treatment completion ranged from 62% to 85% in those being observed at home and between 57% and 83% in clinic observation. On average there was little or no difference between the two locations (RR 1.04, 95% CI 0.91 to 1.17; three trials, 1034 participants, *moderate quality evidence*; [Analysis 2.2](#CD003343-fig-00202){ref-type="fig"}).

One trial, [Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}, had more intense supervision of the observer than the other three trials. This intense supervision however did not improve cure rates (53% for home observation and 49% for clinic observation; RR 1.01, 95% CI 0.91 to 1.11; four trials, 1556 participants, [Analysis 2.3](#CD003343-fig-00203){ref-type="fig"}). This trial however did not report on completion of treatment.

[Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"} had high completion rates (85% in home and 83% in clinic observation arm) but the cure rates were quite low in either arm (43% in both arms).

### 3. Community observed versus family observed {#CD003343-sec3-0024}

Two trials compared community health worker based observation with family based observation ([Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}; [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"}). The trials are described in [Table 11](#CD003343-tbl-0011){ref-type="table"}.

The Nepal trial, [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}, had higher cure rates across the two arms (85% for community and 89% for family observed) compared with [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"} (68% for community and 61% for family observed). There was little or no difference between community and family observation (RR 1.02, 95% CI 0.86 to 1.21; two trials, 1493 participants, *moderate quality evidence*; [Analysis 3.1](#CD003343-fig-00301){ref-type="fig"}). However there was high statistical heterogeneity (I^2^ = 86%; P = 0.009).

Similarly, for the completion of treatment outcome [Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"} had higher rates across the two arms (96% in both arms) compared with [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"} (74% for community and 67% for family observed). There was little or no difference between community and family observation (RR 1.05, 95% CI 0.90 to 1.22; two trials, 1493 participants, *low quality evidence*; [Analysis 3.2](#CD003343-fig-00302){ref-type="fig"}). Again there was high statistical heterogeneity (I^2^ = 87%; P = 0.005).

### 4. DOT versus self‐administered therapy for intravenous drug users {#CD003343-sec3-0025}

One trial, [Chaisson 2001 USA](#CD003343-bbs2-0001){ref-type="ref-list"}, had three arms, supervision at a clinic, peer group supervision and self‐administered treatment. The level of treatment completion was similar in those self‐administering (79%) and those under peer or clinic supervision (79%) (RR 1.00, 95% CI 0.88 to 1.13; one trial, 300 participants, *low quality evidence*; [Analysis 4.1](#CD003343-fig-00401){ref-type="fig"}).

Discussion {#CD003343-sec1-0006}
==========

Summary of main results {#CD003343-sec2-0010}
-----------------------

TB cure and treatment completion were low with self‐administered therapy in these trials, and direct observation did not substantially improve this. Positive effects with direct observation were seen in two trials where patients in the control group were only seen in clinic once a month, but not in the three trials where the controls were seen more frequently (every one or two weeks).

Trials comparing home observation (community observer or family observer) to clinic or healthcare worker led observation did not show any difference in TB cure or treatment completion. Within home‐based direct observation, there were no differences between direct observation by a family member and direct observation by a community health worker.

Overall completeness and applicability of evidence {#CD003343-sec2-0011}
--------------------------------------------------

This Cochrane Review includes trials from both high‐ and low‐burden countries, conducted between 1994 and 2008. Direct observation was implemented in line with current recommendations, and the findings remain applicable to TB treatment programmes today.

Cure and treatment completion with self‐administered treatment were low in these trials, consistent with the outcomes seen in TB programmes at the time, and consequently it is remarkable that direct observation failed to substantially improve these.

One interpretation, offered by [Frieden 2007](#CD003343-bbs2-0036){ref-type="ref-list"}, is that these trials failed to implement direct observation effectively. This interpretation seems unreasonable to us, as the authors of the included trials did what they could to implement direct observation, and it may even be harder to implement, and less successful, outside of a clinical trial . Alternative interpretations are that the health systems were struggling to deliver TB treatment, and direct observation on its own did not resolve these underlying issues, or that TB patients experience financial or logistical barriers to compliance with direct observation. For example, it may cost patients money if they have to visit a health facility as was the case in [Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}.

Direct observation as a strategy is still debated in TB and other chronic diseases. These debates and the findings of this review and others are important given the often huge resource implications of implementing a direct observation therapy programme. In two studies conducted in Brazil to evaluate the cost effectiveness of direct observation strategy; one reported a doubling of indirect costs to the patient compared to self‐administered therapy ([Mohan 2007](#CD003343-bbs2-0047){ref-type="ref-list"}) while the other reported an incremental cost‐effectiveness ratio (ICER) of USD6616 per completed direct observed treatment compared to self‐administered therapy ([Steffen 2010](#CD003343-bbs2-0054){ref-type="ref-list"}).

Agreements and disagreements with other studies or reviews {#CD003343-sec2-0012}
----------------------------------------------------------

The findings of this Cochrane Review are similar to the findings of a meta‐analysis by [Pasipanodya 2013](#CD003343-bbs2-0050){ref-type="ref-list"}, who reported no difference between DOT and self‐administered treatment in terms of reduction in microbiological failure, adverse drug reactions acquired resistance and relapses. The meta‐analysis included ten studies, five RCTs and five observational studies. However, it is worth noting that the included trials were quite heterogenous for a meta‐analysis, the quality scales used were quite unclear and their findings were probably influenced by one observational study.

In their clinical review, [Chan 2002](#CD003343-bbs2-0030){ref-type="ref-list"} reported that direct observation is essential and effective for treatment and, by extension, TB elimination. The review was not systematic and mainly looked at areas where DOT has been done in conjunction with other interventions. It is probable that the other interventions or inputs, rather than specifically observing a patient as they take their medication, were beneficial for benefit, as highlighted by [Volmink 2000b](#CD003343-bbs2-0057){ref-type="ref-list"}. A review by [Tian 2014](#CD003343-bbs2-0055){ref-type="ref-list"} reported that direct observation at a clinic was not more effective than self‐treatment; but that community direct observation may be, with no difference detected between family and non‐family direct observation. The review did not assess the inputs and associated supervision to the extent that we did in this Cochrane Review.

[Ford 2009](#CD003343-bbs2-0034){ref-type="ref-list"}, a review of direct observation in HIV therapy, also reported no effect on virological suppression. Though it might be argued that the therapy of these two diseases is different given that TB is for a finite duration whereas HIV is lifelong and thus adherence issues are different.

Authors\' conclusions {#CD003343-sec1-0007}
=====================

Implications for practiceThe available evidence indicates that direct observation, even when supervised by health staff, does not resolve poor adherence in TB treatment. Given the huge cost implications of direct observation, policy makers therefore might want to rethink their strategies for improving adherence. It is probably worthwhile in considering financial and logistical barriers to care, motivating patients and staff, and enhancing defaulter tracing mechanisms.

Implications for researchThe lack of effects of direct observation in improving cure and completion rates is surprising but reflects the complexity of adherence. Further research in well functioning health systems is needed to assess alternative and complementary strategies to direct observation. Qualitative work focusing on defaulters, where defaulter mechanisms exists and how clinicians interact with patients would especially be important. Evaluation of the cost of DOT for patients and providers would also help in properly assessing these strategies.

What\'s new {#CD003343-sec1-0013}
===========

**DateEventDescription**13 May 2015New search has been performedWe added a trial and a table documenting in detail the inputs to the intervention and control groups. Also, we constructed \'Summary of findings\' tables and carried out additional analyses investigating possible effects of confounding by intense health worker contacts. We rewrote the review and conclusions.13 May 2015New citation required but conclusions have not changedOne trial was added and summary of findings tables were constructed.

History {#CD003343-sec1-0014}
=======

Protocol first published: Issue 4, 2001  Review first published: Issue 4, 2001

**DateEventDescription**11 August 2011New search has been performedCategorised as Current question ‐ no update intended (results conclusive). See \"Published notes\" section for details10 August 2011AmendedPilot classification system added; explanation provided in \"published notes\" section19 September 2008AmendedConverted to new review format with minor editing.13 August 2007New citation required and conclusions have changed2007, Issue 4: One new trial included ([Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}). Also added references to new tuberculosis adherence reviews in the \'Background\' section and reworded objectives to clarify that the review encompasses comparisons between different types of directly observed therapy.15 February 2006Amended2006, Issue 2 ([Volmink 2006](#CD003343-bbs2-0065){ref-type="ref-list"}): Four new trials included ([Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}; [MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}; [Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}; [Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"}).19 November 2003New citation required and conclusions have changed2003, Issue 1: Two trials added ([Chaisson 2001 USA](#CD003343-bbs2-0001){ref-type="ref-list"}; Malotte 2001 USAa).8 August 2001New citation required and major changes2001, Issue 4 ([Volmink 2001](#CD003343-bbs2-0063){ref-type="ref-list"}): first version of this review on directly observed therapy.\
2000, Issue 4 ([Volmink 2000a](#CD003343-bbs2-0062){ref-type="ref-list"}): original review split into a series of Cochrane Reviews, each focusing on particular intervention promotion strategies, such as directly observed therapy in this review.\
1997, Issue 2: review first published as \'Interventions for promoting adherence to tuberculosis management\'.

We acknowledge the Aubrey Sheiham Public Health and Primary Care Scholarships for supporting Jamlick Karumbi in updating this Cochrane Review. The editorial base for the CIDG is funded by the UK Department for International Development (DFID) for the benefit of developing countries.

**Search setCIDG SR^a^CENTRALMEDLINE^b^EMBASE^b^LILACS^b^**1tuberculosistuberculosistuberculosistuberculosistuberculosis2DOT\*PATIENT COMPLIANCEPATIENT COMPLIANCEPATIENT COMPLIANCEDOT\*3directly observed therapyPATIENT PARTICIPATIONPATIENT PARTICIPATIONPATIENT MONITORINGsupervision42 or 3patient monitoringMOTIVATIONDOT\$2 or 351 and 4MOTIVATIONDECISION SUPPORT TECHNIQUESdirectly observed therapy1 and 46---DECISION SUPPORT TECHNIQUESDOT\*compliance---7---DOT\*directly observed therapymotivation---8---directly observed therapycompliancepatient\$---9---compliancepatient\*defaulter\$---10---defaulter\*defaulter\*adheren\$---11---adheren\*adheren\*supervis\$---12---supervision\*supervis\*2‐11/or---13---2‐12/or2‐12/or1 and 12---14---1 and 131 and 13Limit 13 to human---15------Limit 14 to human------

^a^CIDG Specialized Register.  ^b^Search terms used in combination with the search strategy for retrieving trials developed by Cochrane ([Higgins 2011](#CD003343-bbs2-0038){ref-type="ref-list"}); upper case: MeSH or EMTREE heading; lower case: free text term.

###### Directly observed versus self‐administered

  Outcome or subgroup title                                                                                                                   No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Cure (negative sputum smear in last month of Rx in patients +ve initially)](#CD003343-fig-00101){ref-type="fig"}                         5                1645                  Risk Ratio (M‐H, Random, 95% CI)   1.08 \[0.91, 1.27\]
  [2 Cure (by intensity of monitoring in control group)](#CD003343-fig-00102){ref-type="fig"}                                                 5                1645                  Risk Ratio (M‐H, Fixed, 95% CI)    1.07 \[1.00, 1.15\]
  2.1 Monthly monitoring of patients in self administered group                                                                               2                900                   Risk Ratio (M‐H, Fixed, 95% CI)    1.15 \[1.06, 1.25\]
  2.2 Once every two weeks monitoring of patients in self‐administered group                                                                  1                497                   Risk Ratio (M‐H, Fixed, 95% CI)    0.96 \[0.83, 1.12\]
  2.3 Weekly monitoring of patients in self‐administered group                                                                                2                248                   Risk Ratio (M‐H, Fixed, 95% CI)    0.90 \[0.68, 1.21\]
  [3 Treatment completion (both with smear sputum test at end and those without)](#CD003343-fig-00103){ref-type="fig"}                        6                1839                  Risk Ratio (M‐H, Random, 95% CI)   1.07 \[0.96, 1.19\]
  [4 Treatment completion (grouped by frequency of monitoring in the self‐administered therapy group)](#CD003343-fig-00104){ref-type="fig"}   6                1839                  Risk Ratio (M‐H, Random, 95% CI)   1.07 \[0.96, 1.19\]
  4.1 Monthly monitoring of self‐administered treatment                                                                                       3                1073                  Risk Ratio (M‐H, Random, 95% CI)   1.12 \[0.95, 1.31\]
  4.2 Once every two weeks monitoring of self‐administered treatment                                                                          1                497                   Risk Ratio (M‐H, Random, 95% CI)   0.99 \[0.87, 1.14\]
  4.3 Weekly monitoring of self‐administered treatment                                                                                        2                269                   Risk Ratio (M‐H, Random, 95% CI)   1.04 \[0.74, 1.46\]

![Analysis\
Comparison 1 Directly observed versus self‐administered, Outcome 1 Cure (negative sputum smear in last month of Rx in patients +ve initially).](nCD003343-CMP-001-01){#CD003343-fig-00101}

![Analysis\
Comparison 1 Directly observed versus self‐administered, Outcome 2 Cure (by intensity of monitoring in control group).](nCD003343-CMP-001-02){#CD003343-fig-00102}

![Analysis\
Comparison 1 Directly observed versus self‐administered, Outcome 3 Treatment completion (both with smear sputum test at end and those without).](nCD003343-CMP-001-03){#CD003343-fig-00103}

![Analysis\
Comparison 1 Directly observed versus self‐administered, Outcome 4 Treatment completion (grouped by frequency of monitoring in the self‐administered therapy group).](nCD003343-CMP-001-04){#CD003343-fig-00104}

###### Home observed versus clinic observed

  Outcome or subgroup title                                                                                                                                 No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Cure (having a negative sputum smear test in the last month of treatment having been smear‐positive initially)](#CD003343-fig-00201){ref-type="fig"}   4                1556                  Risk Ratio (M‐H, Random, 95% CI)   1.02 \[0.88, 1.18\]
  [2 Treatment completion (both with smear sputum test at end and those without)](#CD003343-fig-00202){ref-type="fig"}                                      3                1034                  Risk Ratio (M‐H, Random, 95% CI)   1.04 \[0.91, 1.17\]
  [3 Cure (stratified by intensity of observation)](#CD003343-fig-00203){ref-type="fig"}                                                                    4                1556                  Risk Ratio (M‐H, Fixed, 95% CI)    1.01 \[0.91, 1.11\]
  3.1 DOT (Intense supervision of observer)                                                                                                                 1                522                   Risk Ratio (M‐H, Fixed, 95% CI)    1.08 \[0.91, 1.28\]
  3.2 Routine supervision of DOT                                                                                                                            3                1034                  Risk Ratio (M‐H, Fixed, 95% CI)    0.98 \[0.86, 1.10\]

![Analysis\
Comparison 2 Home observed versus clinic observed, Outcome 1 Cure (having a negative sputum smear test in the last month of treatment having been smear‐positive initially).](nCD003343-CMP-002-01){#CD003343-fig-00201}

![Analysis\
Comparison 2 Home observed versus clinic observed, Outcome 2 Treatment completion (both with smear sputum test at end and those without).](nCD003343-CMP-002-02){#CD003343-fig-00202}

![Analysis\
Comparison 2 Home observed versus clinic observed, Outcome 3 Cure (stratified by intensity of observation).](nCD003343-CMP-002-03){#CD003343-fig-00203}

###### Community observed vs family observed

  Outcome or subgroup title                                                                                                                                 No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Cure (having a negative sputum smear test in the last month of treatment having been smear‐positive initially)](#CD003343-fig-00301){ref-type="fig"}   2                1493                  Risk Ratio (M‐H, Random, 95% CI)   1.02 \[0.86, 1.21\]
  [2 Treatment completion (both with smear sputum test at end and those without)](#CD003343-fig-00302){ref-type="fig"}                                      2                1493                  Risk Ratio (M‐H, Random, 95% CI)   1.05 \[0.90, 1.22\]

![Analysis\
Comparison 3 Community observed vs family observed, Outcome 1 Cure (having a negative sputum smear test in the last month of treatment having been smear‐positive initially).](nCD003343-CMP-003-01){#CD003343-fig-00301}

![Analysis\
Comparison 3 Community observed vs family observed, Outcome 2 Treatment completion (both with smear sputum test at end and those without).](nCD003343-CMP-003-02){#CD003343-fig-00302}

###### Injecting drug users

  Outcome or subgroup title                                       No. of studies   No. of participants   Statistical method                Effect size
  --------------------------------------------------------------- ---------------- --------------------- --------------------------------- --------------------
  [1 Treatment completion](#CD003343-fig-00401){ref-type="fig"}   1                300                   Risk Ratio (M‐H, Fixed, 95% CI)   1.0 \[0.88, 1.13\]

![Analysis\
Comparison 4 Injecting drug users, Outcome 1 Treatment completion.](nCD003343-CMP-004-01){#CD003343-fig-00401}

Characteristics of included studies \[ordered by study ID\] {#CD003343-sec2-0016}
===========================================================

[Chaisson 2001 USA](#CD003343-bbs2-0001){ref-type="ref-list"}MethodsGeneration of allocation sequence: randomized, with factorial overlay; computer‐generated random numbers.\
Allocation concealment: not stated.\
Blinding: none.\
Completeness of follow‐up: 88%.ParticipantsNumber: 300 randomized; 73% men; 85% unemployed; 27% with documented human immunodeficiency virus (HIV) infection.\
Included: adult, intravenous drug users with positive tuberculin skin test (at least 10 mm induration or 5 mm if HIV positive); given isoniazid preventive therapy for 6 months.\
Excluded: people with active TB.InterventionsDOT twice weekly by outreach nurse at clinic or community location.Daily self‐administration of treatment, monthly peer counselling group meetings with lunch, and clinical assessments by a nurse; peer counsellor was a former injection user who had completed preventive therapy, and who was trained in counselling and supervised by a health educator.Daily self‐administration of treatment with monthly clinic assessment; factorial design with immediate or deferred US\$10 stipend at the end of each month; deferred payments credited each month and given when treatment completed or participant withdrew.Outcomes6 months treatment completed, defined as 80% or more of treatments taken (observed for DOT group and 6 monthly visits plus reporting that at least 80% medication taken during a month for other groups).Pill counts.Isoniazid metabolites in the urine.Electronically monitored bottle opening in a subset.NotesLocation: Baltimore City Health Department TB Clinic, USA.\
Date: 1995 to 1997.\
Duration of DOT duration not stated.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"generated using computer algorithm\".Allocation concealment (selection bias)Unclear riskNo details reported.Blinding of outcome assessment (detection bias)   All outcomesHigh riskNone. \"Blinding of the study was not possible.\"Incomplete outcome data (attrition bias)   All outcomesUnclear riskThere were losses to follow‐up in each arm though not differential there are no reports on them.Selective reporting (reporting bias)Low riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.[Hsieh 2008 TWN](#CD003343-bbs2-0002){ref-type="ref-list"}MethodsGeneration of allocation sequence: not stated.\
Randomization: stratified.\
Allocation concealment: not stated.\
Blinding: not stated.\
Completeness of follow‐up: no losses (18/114) dropped to enable matching.ParticipantsNumber; 96 randomized into three groups; Matched by age and gender; confirmed TB diagnosis and over 18 yrs.InterventionsCase manager directly supervised medicine intake for first two months, then self‐administration with weekly unscheduled visit.Self‐administration with monthly unscheduled visit by the case manager.Routine care in the ward with monthly visit by case manager.OutcomesMonthly adherence levels (\>80% or \<80%) \>80% defined as at most 5 drug interruptions per month.Completion rate ‐ Proportion of patients who completed the treatment course.Success rate ‐ Proportion of patients who completed treatment plus confirmed negative sputum result.NotesLocation: Taiwan.\
Trial period: May 2002 to July 2003.\
Duration of observation was 6 months.\
The patients were not given a choice of DOT observer.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"There were 114 subjects meeting the sampling criteria who were then matched by age and gender and randomized into one of three groups\".Allocation concealment (selection bias)Unclear riskNo details reported.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias)   All outcomesUnclear risk18/114 dropped to enable matching.Selective reporting (reporting bias)Unclear riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.[Kamolratanakul 1999 THA](#CD003343-bbs2-0003){ref-type="ref-list"}MethodsGeneration of allocation sequence: central block random allocation scheme prepared for each of 15 trial sites; random‐number table used.\
Allocation concealment: none.\
Blinding: no blinding of assessors.\
Completeness of follow‐up: 100% (no losses).ParticipantsNumber: 837 randomized; 73% male.\
Included: new smear positive adults (aged 15+).InterventionsDaily supervision: participants chose their supervisor from (a) health centre staff, (b) community members, or (c) family members; for (b) and (c) health workers visited homes twice monthly (first 2 months) or monthly for checking of treatment cards, pill counts, and urine tests.Self‐administration of treatment: 1 month drug supply given at diagnosis and after each follow‐up visit; no treatment supervision between visits.\
All participants received the same drug regimen: isoniazid‐rifampicin‐pyrazinamide‐ethambutol for 2 months and isoniazid‐rifampicin for 4 months.OutcomesCure rate (primary outcome): completed 6 months antituberculous therapy, with 2 negative sputum exams, 1 at end of treatment.Treatment completion: completed 6 months antituberculous therapy but less than 2 sputum exams.Sputum conversion rate: negative sputum at end of third month.Percentage defaults.Percentage transfers.Caseholding rate.NotesLocation: Thailand.\
Date: 1996 to 1997.\
Duration of\
DOT not stated.\
Informed consent not obtained as participants were not told that they were participating in a study.\
Choice of supervisor for DOT participants: 352 chose a family member; 34 chose a community member; and 24 chose health centre staff.\
One participant in daily supervision arm excluded due to protocol violation so not strictly intention‐to‐treat.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskGenerated using random number tables.Allocation concealment (selection bias)Unclear riskInadequate information.Blinding of outcome assessment (detection bias)   All outcomesHigh riskInvestigators not blinded though the patients were blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskThere were no exclusions.Selective reporting (reporting bias)Unclear riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.[Lwilla 2003 TZA](#CD003343-bbs2-0004){ref-type="ref-list"}MethodsCluster‐RCT: 9 pairs of centres matched by type and size.\
Generation of allocation sequence: unclear.\
Allocation concealment: unclear.\
Blinding: none.\
Completeness of follow‐up: 87% at 2 months and 69% at 7 months.ParticipantsNumber: 18 clusters randomized; 522 participants; mean age 35; 60% male.\
Included: new smear positive adults.InterventionsCommunity‐based DOT: daily observation by community health volunteer (site not stated) for intensive 2‐month treatment period; health worker visited volunteer every 2 weeks and district co‐ordinator visited volunteer monthly; at each visit participants\' treatment card checked and drugs counted.Institution‐based DOT: required to attend health facility daily for 2 months, and then monthly after this.\
Continuation phase of 6 months: both groups managed the same and expected to self‐administer treatment daily.OutcomesSputum negative at 2 months (primary outcome).Cure at 7 months (sputum negative at 2 months and at 5 to 7 months).NotesLocation: Tanzania.\
Date: 1999 to 2000.\
Duration of DOT not stated.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo details reported.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding of outcome assessment (detection bias)   All outcomesHigh riskNone. \"This study was an unmasked cluster randomized trial\".Incomplete outcome data (attrition bias)   All outcomesHigh riskOnly 68% (311/437 participants) were evaluated at 7 months. (This could affect the cure outcome).Selective reporting (reporting bias)Low riskAll outcomes stated in the methodology are reported.Recruitment biasUnclear riskNo details of any shifting, though the cluster sizes varied from as low as 2 persons to 232 persons.Baseline imbalanceLow riskClusters were similar though the size varied and one cluster had possibly a more sicker patient profile due to its highly specialized nature.Loss of clustersUnclear riskOne cluster in the community based intervention did not have patients hence was dropped in the analysis.Incorrect analysisLow riskCluster adjusted hence comparable to other RCTs randomizing individuals.[MacIntyre 2003 AUS](#CD003343-bbs2-0005){ref-type="ref-list"}MethodsQuasi‐RCT\
Generation of allocation sequence: alternate allocation\
Concealment of allocation: none\
Blinding: assessment of urinary isoniazid blinded\
Completeness of follow‐up: not statedParticipantsNumber: 173 recruited, mostly foreign nationals; male 51%; mean age 41 (range 14 to 83).\
Included: new TB participants.\
Excluded: multiple‐drug resistant TB; relapsed TB; human immunodeficiency virus (HIV)‐positive cases; and nontuberculous mycobacterial infections.InterventionsFamily‐based DOT: daily observation by a nominated family member who received education and was expected to record participant compliance with pill taking; weekly phone calls from a nurse; nurse on call; nurse home visit every 2 weeks.Self‐administration of treatment: daily.\
Both groups had monthly visits to health facilities and standardized recording charts.OutcomesTreatment completion measured by:\
Percentage clinic attendances to collect drugs.Urinary isoniazid (6 random checks over months; all had to be \> 0).NotesLocation: Australia.\
Date: 1998 to December 2000.\
Duration of DOT not stated.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskNot randomly. \"Patients were systematically allocated to receive FDOT or ST\".Allocation concealment (selection bias)High riskSystematic allocation \"The first patient was randomly allocated to the ST arm, every second patient was allocated to FDOT, and the remainder to ST\".Blinding of outcome assessment (detection bias)   All outcomesLow riskAssessors were blinded.Incomplete outcome data (attrition bias)   All outcomesUnclear riskInsufficient information as to what happened to those who refused family DOT.Selective reporting (reporting bias)Unclear riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.[Newell 2006 NPL](#CD003343-bbs2-0006){ref-type="ref-list"}MethodsCluster‐RCT.\
Generation of allocation sequence: 5 randomly selected districts allocated to each arm; the name of each district was written on an individual paper and randomly drawn from a basket.\
Allocation concealment: method not stated.\
Blinding: laboratory technicians assessing the primary outcomes were blinded.\
Completeness of follow‐up: 100% (no clusters or individuals lost).ParticipantsNumber: 10 districts with 907 people randomized; all smear positive; 67% male.\
Included: people with TB (aged 15+); new smear‐positive cases, diagnosed at health facilities in the trial area; human immunodeficiency virus (HIV) status not known.InterventionsCommunity‐based DOT: daily treatment supervised by a female community health worker (unpaid volunteer selected by the district health authority) or village health worker (community worker paid by government). Patients mainly visited at home, but occasionally patients met their supervisor at her home. Supervision was for the duration of treatment with drugs provided to the supervisor monthly. Tracing by the supervisor was undertaken for patients who discontinued treatment.Family‐based DOT: daily supervision by a household member chosen by the participant with drugs provided to the supervisory weekly. Government workers traced those who discontinued treatment.OutcomesTreatment success: cure plus treatment completion (primary).Treatment success compared with the WHO target of 85%.Estimated case detection rate with the WHO target of 70%.Compare the above rates in men and women.NotesLocation: hill and mountain districts of Nepal.\
Date: 2002 to 2003.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskInsufficient information on selection of 10 districts out of 17.Allocation concealment (selection bias)Low riskRandomly picked papers from an opaque bag.Blinding of outcome assessment (detection bias)   All outcomesLow riskAssessors were blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskNo cluster was lost to follow‐up or excluded.Selective reporting (reporting bias)Low riskAll outcomes stated in the methodology are reported.Recruitment biasUnclear riskNot reported if there were patients who shifted to the different intervention arms, though they were separated by a mountainous region.Baseline imbalanceLow riskCharacteristics similar.Loss of clustersLow riskNo loss reported.Incorrect analysisLow riskCluster adjustment done.[Walley 2001 PAK](#CD003343-bbs2-0007){ref-type="ref-list"}MethodsGeneration of allocation sequence: computer‐generated random numbers.\
Allocation concealment: opaque, sealed envelopes.\
Blinding: assessors blinded.\
Completeness of follow‐up: not stated.ParticipantsNumber: 497 randomized; 51.3% male.\
Included: adults (aged 15+); new smear‐positive cases.InterventionsDOT by a health worker at a health facility that met \"access criteria\" or a community health worker at or near the participant\'s home: access criteria were return journey from the participant\'s home to facility \< 2 km, \< 2 hr duration, and \< 10 rupees, and for unmarried women an accompanying relative was available; participants had to attend a health facility or meet a community health worker 6 times per week for 2 months to take their drugs; thereafter they self‐administered drugs that the participants collected twice a month.DOT by a family member chosen by the participant.Self‐administration of drugs collected by participant fortnightly.\
All participants received isoniazid‐rifampicin‐pyrazinamide‐ethambutol for 2 months and isoniazid‐ethambutol for 6 months.OutcomesCure: sputum negative at 7 or 8 months and on at least 1 previous occasion.Treatment completion: treatment completed, but smear results not available on at least 2 occasions before completion of treatment.Treatment failure.Death.Default.Transferred out.NotesLocation: Pakistan\
Date: 1996 to 1998***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated random sequence.Allocation concealment (selection bias)Low riskOpaque envelopes were used and third party calls.Blinding of outcome assessment (detection bias)   All outcomesLow riskOutcome assessors  were blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskThere were no exclusions after randomization.Selective reporting (reporting bias)Low riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.[Wandwalo 2004 TZA](#CD003343-bbs2-0008){ref-type="ref-list"}MethodsGeneration of allocation sequence: coin tossing in each of 5 clinics.\
Allocation concealment: none.\
Blinding: none.\
Completeness of follow‐up: 100% (no losses).ParticipantsNumber: 587 randomized; 322 smear positive, 182 smear negative, and 83 extrapulmonary TB; 57% male.\
Included: people with TB (aged 5+); new smear positive, smear negative, and extrapulmonary cases; human immunodeficiency virus (HIV) status not known.\
Excluded: previously treated for TB; severe illness; transferred from another clinic; previously enrolled in the study.InterventionsCommunity‐based DOT: daily treatment supervised at home by \'guardian\' (usually a family member) during 2‐month intensive period; supervisors trained to observe drug taking, encourage participants to complete treatment, keep records, collect drugs, and assess drug side effects; during first 2 months participants received \'spot\' visits by health workers who conducted treatment card checks and pill counts; during first 2 months participants also requested to attend clinic every 2 weeks for clinical review and progress monitoring.Health facility‐based DOT: daily supervision at clinic by health workers during the 2 month intensive period.\
Apart from the observation option participants received the same standardized management including drug therapy.OutcomesTreatment success: cure plus treatment completion.Cure: smear positive initially and negative at 7 or 8 months and on at least 1 previous occasion.Treatment completion: positive results initially, negative at 2 months and no results at end of treatment; or smear negative initially and received treatment on clinical grounds; or those who completed full course of treatment but had no initial or end‐of‐treatment results.Death: from all causes.Treatment failure: participants who remained or became smear positive or 5 months or later.Default: failed to collect medication for \> 2 consecutive months.Transferred out: transferred to a clinic in another area.NotesLocation: Dar es Salaam, Tanzania.\
Date: 2001 to 2003.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Randomly by coin toss\".Allocation concealment (selection bias)High riskNone.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias)   All outcomesLow riskNo exclusions.Selective reporting (reporting bias)Low riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.[Wright 2004 SWZ](#CD003343-bbs2-0009){ref-type="ref-list"}MethodsGeneration of allocation sequence: unclear; stratified into adults and children; then, within each group, randomized by type of TB (sputum positive, sputum negative, extrapulmonary, relapse).\
Allocation concealment: unclear; sealed, sequentially numbered envelopes not stated if opaque.\
Blinding: assessors of sputum results blinded.\
Completeness of follow‐up: 98%.ParticipantsNumber: 1353 randomized; 55% male; most 15+ years.\
Included: adults and children with smear positive or negative, extrapulmonary TB, or relapse of previously treated TB.\
Excluded: died before discharge; or too ill to receive outpatient treatment; lived in area without treatment supporter; or referred in after treatment commenced.InterventionsDOT by community health worker: participants visited for observation daily; community health worker trained to provide daily treatment supervision, record adherence on Treatment Support Card, remind participants who did not report for treatment, and notify diagnostic centre about those who defaulted treatment.DOT by family member: family member or carer chosen by participant trained to provide daily treatment supervision, record adherence on Treatment Support Card, and remind participants who did not report for treatment; participants also required to visit the community health worker weekly to check side effects and adherence and receive health education; defaulters reported to the diagnostic centre.OutcomesCure or treatment completion: cure defined as smear negative at 6 months and on at least 1 previous occasion; treatment completion defined as treatment completed but smear results not available on at least 2 occasions before treatment completion.Death.Treatment failure: remained or became smear positive at ≥ 5 months.Default: failed to collect medication for \> 2 consecutive months.Transferred out: formally transferred to another centre.NotesLocation: Swaziland.\
Date: 2000 to 2002.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskInsufficient information.Allocation concealment (selection bias)Unclear riskUse of sealed envelopes not clear whether opaque. \"\
sealed, sequentially numbered, stratum specific envelopes containing treatment assignments\".Blinding of outcome assessment (detection bias)   All outcomesLow riskLaboratory assessors were blinded.Incomplete outcome data (attrition bias)   All outcomesLow riskNon differential loss to follow‐up (4/664 and 5/662).Selective reporting (reporting bias)Unclear riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.[Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}MethodsGeneration of allocation sequence: computer‐generated random numbers.\
Allocation concealment: consecutively numbered, opaque, sealed envelopes in each of 5 clinics.\
Blinding: none.\
Completeness of follow‐up: 114/120 (95%) in 1 trial and 102/120 (85%) in other trial excluded from analysis.ParticipantsNumber: 216 included in analysis; 62% male; 57% \< 35 years.\
Included: adults (aged 15+) with pulmonary TB; both new and re‐treatment cases.\
Excluded: severe disease or multiple drug resistance; treatment at a non‐study clinic for more than 2 weeks; need to be supervised at school or at the workplace; and leaving the area within a month.InterventionsDOT by clinic nurses: participants asked to visit the clinic 5 days a week for 8 weeks (new participants) or for 12 weeks (re‐treatment participants); thereafter expected attendance was 3 days a week for the continuation phase; clinic visits restricted to normal working hours and adherence card signed and dated by a nurse at each visit and kept at the clinic.Self‐administration of treatment: participants had to visit clinic once a week or send a relative to collect drugs; participants completed their own adherence card for every day of drug taking and a nurse recorded the weekly drug collection; adherence card handed to nurse at the weekly clinic visit.\
New cases received Rifater (combined rifampicin‐isoniazid‐pyrazinamide) for 8 weeks followed by Rifinah 4 (combined rifampicin‐isoniazid) plus additional isoniazid for 18 weeks.\
Retreatment participants received Rifater plus ethambutol for 12 weeks and Rifinah plus rifampicin‐ethambutol for 22 weeks.Outcomes\"Successful treatment\" included those who were cured and those who completed treatment; \"cured\" applied to those who converted from a positive smear or culture, or both, to a negative smear or culture, or both, at the end of treatment (6 months for new participants and 8 months for re‐treatment participants); \"treatment completed\" referred to participants who (a) completed the full course of treatment but had no pretreatment or post‐treatment bacteriological results; (b) had negative pretreatment results and had been treated on clinical grounds; or (c) had positive pretreatment results, negative results after 2 months and no post‐treatment results.\"Treatment failure\" applied to participants with a positive smear or culture at the end of treatment.\"Treatment interrupters\" applied to participants who stopped taking treatment for 8 or more weeks during the treatment period.Transfer to another treatment facility.Death from TB or other causes while on treatment.NotesLocation: 1 trial in each of 2 low‐income communities near Cape Town, South Africa.\
Date: 1994 to 1995.\
Results combined.\
54 participants in 1 trial allocated to community supervision not reported in this paper.\
Exclusions from analysis: trial 1 (6 cases of multiple drug resistance) and trial 2 (12 cases of multiple drug resistance and 6 not TB).\
Number of exclusions per arm of the 2 trials not given.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Random sequence generated by a computer algorithm\".Allocation concealment (selection bias)Low risk\"Consecutively numbered opaque sealed envelops were used\".Blinding of outcome assessment (detection bias)   All outcomesUnclear riskInsufficient information on whether there was any blinding or not.Incomplete outcome data (attrition bias)   All outcomesHigh riskThere was differential exclusions between the intervention and control arms.Selective reporting (reporting bias)Low riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.[Zwarenstein 2000 ZAF](#CD003343-bbs2-0011){ref-type="ref-list"}MethodsGeneration of allocation sequence: computer‐generated random numbers.\
Allocation concealment: consecutively numbered, opaque, sealed envelopes.\
Blinding: none.\
Completeness of follow‐up: not stated.ParticipantsNumber: 174 randomized.\
Included: new or re‐treatment participants aged 15+ who were sputum or culture positive.InterventionsDOT by clinic nurses (see [Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}).Self‐administration (see [Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}).DOT by lay health workers: participants took drugs at home of a lay health worker under supervision; if participant missed treatment for 1 day, a lay health worker visited participant\'s home and if necessary a member of the South African Tuberculosis Association (SANTA) also visited the participant.OutcomesAs for [Zwarenstein 1998 ZAF](#CD003343-bbs2-0010){ref-type="ref-list"}.NotesLocation: 4 clinics in a township near Cape Town, South Africa.\
Date: 1994 to 1995.\
18 participants excluded from analysis: 12 with multiple‐drug resistant TB and 6 not TB.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom sequence generated by a computer algorithm.Allocation concealment (selection bias)Low riskConsecutively numbered opaque sealed envelopes.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskInsufficient information on whether there was any blinding or not.Incomplete outcome data (attrition bias)   All outcomesLow riskThere were exclusions though not differentiated between intervention arms.\
\"After exclusion of 12 MDR and six non‐TB patients\"*.*Selective reporting (reporting bias)Unclear riskAll outcomes stated in the methodology are reported.Other biasUnclear riskNot applicable.

Characteristics of excluded studies \[ordered by study ID\] {#CD003343-sec2-0017}
===========================================================

StudyReason for exclusion[Batki 2002](#CD003343-bbs2-0012){ref-type="ref-list"}Compared direct observation plus with methadone treatment for injecting drug users with routine TB treatment without methadone.[Carroll 2004](#CD003343-bbs2-0013){ref-type="ref-list"}Before‐and‐after study; no control group.[Hwang 2004](#CD003343-bbs2-0014){ref-type="ref-list"}Not randomized.[Jasmer 2004](#CD003343-bbs2-0015){ref-type="ref-list"}Different criteria for allocation to self‐administration or direct observation.[Lewin 2004](#CD003343-bbs2-0016){ref-type="ref-list"}An educational intervention was evaluated.[Malotte 2001](#CD003343-bbs2-0017){ref-type="ref-list"}Evaluates incentives for IV drug users within the context of a direct observation programme.[Matthew 2002](#CD003343-bbs2-0018){ref-type="ref-list"}Cohort study.[Moulding 2002](#CD003343-bbs2-0019){ref-type="ref-list"}Trial evaluating devices that monitor treatment using uranium along a strip of photographic film.[Pungrassami 2002a](#CD003343-bbs2-0020){ref-type="ref-list"}Not randomly allocated; A publication reporting same data as [Pungrassami 2002b](#CD003343-bbs2-0021){ref-type="ref-list"}.[Pungrassami 2002b](#CD003343-bbs2-0021){ref-type="ref-list"}Not randomly allocated; A publication reporting same data as [Pungrassami 2002a](#CD003343-bbs2-0020){ref-type="ref-list"}.[Sorete‐Abore 2002](#CD003343-bbs2-0022){ref-type="ref-list"}Cohort study.[Tandon 2002](#CD003343-bbs2-0023){ref-type="ref-list"}Described as a RCT, but the randomization led to very different numbers in the 2 groups; subsequently over 50 participants (out of a total of 379) crossed over from self‐treatment to direct observation and were excluded from the analysis; little detail for the rest of the study provided.[Thiam 2007](#CD003343-bbs2-0024){ref-type="ref-list"}Multifaceted intervention including DOT.[Toyota 2003](#CD003343-bbs2-0025){ref-type="ref-list"}Patients in hospital.

Jimmy Volmink and Paul Garner carried out the first edition of this Cochrane Review ([Volmink 2001](#CD003343-bbs2-0063){ref-type="ref-list"}) and review updates ([Volmink 2003](#CD003343-bbs2-0064){ref-type="ref-list"}; [Volmink 2006](#CD003343-bbs2-0065){ref-type="ref-list"}; [Volmink 2007](#CD003343-bbs2-0066){ref-type="ref-list"}). Jamlick Karumbi performed this review update, assisted by Paul Garner. All review authors reviewed and approved the final manuscript.

Internal sources {#CD003343-sec2-0014}
================

South African Medical Research Council, South Africa.Liverpool School of Tropical Medicine, UK.

External sources {#CD003343-sec2-0015}
================

Department for International Development, UK.

As a result of the earlier editions of this review from the mid 1990s, PG has become recognised and associated with the continued debate about whether DOT should be central to national programmes in low‐ and middle‐income countries.
